By rray, 9 February, 2023 Considering trade off decisions between drug classes efficacy wt effects cost etc
By rray, 9 February, 2023 In pts who haven t achieved their individualized weight goals additional wt mgmt interventions e g intensification of lifestyle modifications structured wt mgmt programs pharmacologic agents or metabolic surgery as appropriate are recommended A
By rray, 9 February, 2023 In pts who haven t achieved their individualized glycemic goals selection of subsequent glucose lowering tx should account for individualized glycemic and wt goals plus presence of other metabolic comorbidities and risk of hypoglycemia A
By rray, 9 February, 2023 In pts w o CV and or kidney dz pharmacologic agents should address both individualized glycemic and wt goals A
By rray, 9 February, 2023 Consider early combo tx at tx initiation to shorten time to attainment of individualized tx goals A
By rray, 9 February, 2023 Re evaluate medication plan and medication taking behavior at regular intervals e g q3 6mo and adjust as needed to incorporate specific factors that impact choice of tx E
By rray, 9 February, 2023 Don t delay tx modification intensification or deintensification for adults not meeting individualized tx goals A
By rray, 9 February, 2023 Use pharmacological strategies that provide sufficient effectiveness to achieve and maintain intended tx goals A
By rray, 9 February, 2023 Glucose lowering tx plan should consider approaches that support wt mgmt goals A
By rray, 9 February, 2023 Use a person centered shared decision making approach to guide choice of pharmacologic agents Consider effects on CV and renal comorbidities effectiveness hypoglycemia risk impact on wt cost and access risk for adverse reactions and tolerability and indiv